<DOC>
	<DOCNO>NCT00411541</DOCNO>
	<brief_summary>Studies 1970s 1980s suggest outcome childhood acute lymphoblastic leukemia could improve intensification conventional continuation chemotherapy pulse vincristine sulfate steroid . We aim investigate efficacy toxic effect vincristine-dexamethasone pulse addition continuation-therapy phase large cohort child intermediate-risk disease treat BFM treatment strategy</brief_summary>
	<brief_title>Pulses Vincristine Dexamethasone BFM Protocols Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The study enrol child 8 participate organization . All child treat similar protocol base BFM treatment strategy , include induction , consolidation , reinduction continuation-therapy phase . At begin continuation-therapy phase , patient complete remission randomly assign either treatment control group . Control patient give conventional mercaptopurine methotrexate chemotherapy . Patients treatment arm also give pulse vincristine ( 1.5 mg/sqm weekly 2 week ) dexamethasone ( 6 mg/sqm daily 7 day ) every 10 week six cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>age &lt; 1 &gt; 5 year white blood cell count diagnosis &gt; =20000 prednisone poor response complete remission end induction ( IA ) ( 9,22 ) clonal translocation ( 4,11 ) clonal translocation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>acute lymphoblastic leukemia , maintenance , BFM protocol</keyword>
	<keyword>intermediate risk childhood acute lymphoblastic leukemia</keyword>
</DOC>